<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814589</url>
  </required_header>
  <id_info>
    <org_study_id>LC00-065</org_study_id>
    <nct_id>NCT04814589</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Ezetimibe Tablets in Healthy Subjects</brief_title>
  <official_title>Bioequivalence of Ezetimibe Tablets in Healthy Subjects: A Single-dose and Two-period Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cao Yu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Qingdao University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the relevant provisions of bioequivalence test, ezetimibe Tablets (test&#xD;
      preparation, T, 10mg / tablet) provided by China Resources Saike Pharmaceutical Co., Ltd.&#xD;
      were compared with Ezetrol ® (reference preparation, R, 10mg / tablet) produced by MSD Pharma&#xD;
      (Singapore) Pte. Ltd. to evaluate the bioequivalence of single dose in healthy subjects under&#xD;
      fasting and fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluation of Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)0-t</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluation of Area under the plasma concentration versus time curve (AUC)0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)0-∞</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluation of Area under the plasma concentration versus time curve (AUC)0-∞</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>90 days</time_frame>
    <description>Collection of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal blood pressure</measure>
    <time_frame>90 days</time_frame>
    <description>Monitor both systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal temperature</measure>
    <time_frame>90 days</time_frame>
    <description>Monitor the temperature</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Therapeutic Equivalency</condition>
  <arm_group>
    <arm_group_label>ezetimibe Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ezetimibe tablets test formulation at a single dose of 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ezetimibe tablets(Ezetrol ®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ezetimibe tablets reference formulation at a single dose of 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe tablets</intervention_name>
    <description>The subjects randomly received single oral administration of ezetimibe tablets 10 mg.</description>
    <arm_group_label>ezetimibe Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe tablets(Ezetrol ®)</intervention_name>
    <description>The subjects randomly received single oral administration of ezetimibe tablets 10 mg.</description>
    <arm_group_label>ezetimibe tablets(Ezetrol ®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female subjects ≥18 years of age, with appropriate sex ratio;&#xD;
&#xD;
          -  The body mass index is in the range of 19.0-26.0 kg/m2 (including the critical value).&#xD;
             The weight of male is not less than 50.0 kg, and that of female is not less than 45.0&#xD;
             kg.&#xD;
&#xD;
          -  The following examination show that the indicators are normal or abnormal without&#xD;
             clinical significance. The examination including: Vital signs, physical examination,&#xD;
             blood routine, blood biochemistry, urinalysis, pregnancy test for female, serological&#xD;
             tests for hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV),&#xD;
             and syphilis virus, 12 lead ECG, breath test for alcohol, drug abuse test and Nicotine&#xD;
             test.&#xD;
&#xD;
          -  The subjects have no family planning within 3 months and could select contraceptive&#xD;
             method.&#xD;
&#xD;
          -  Before the study, all subjects have been informed of the study's purpose, protocal,&#xD;
             benefits, and risks, and signed the informed consent voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alanine aminotransferase &gt;1.0×ULN ,Aspartate aminotransferase &gt;1.0×ULN or Total&#xD;
             bilirubin &gt;1.0×ULN.&#xD;
&#xD;
          -  Subjects with allergic constitution.&#xD;
&#xD;
          -  Being allergy to the study medications, smoking, alcohol abuse.&#xD;
&#xD;
          -  Participation in another clinical trial within 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yu Cao, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>the study director of phase I clinical research center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yu Cao, doctor</last_name>
    <phone>86 18661809090</phone>
    <email>caoyu1767@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phase Ⅰ Clinical Research Center</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yu Cao, Doctor</last_name>
      <phone>86 18661809090</phone>
      <email>caoyu1767@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Hospital of Qingdao University</investigator_affiliation>
    <investigator_full_name>Cao Yu</investigator_full_name>
    <investigator_title>Director, Head of Phase I clinical research center, Principal Investigator, Clinical Professor.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

